{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+3+of+Aluminum+Adjuvant", "query": { "intervention": "Dose 3 of Aluminum Adjuvant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+3+of+Aluminum+Adjuvant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T06:39:14.199Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01995617", "title": "Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Streptococcus Pneumoniae" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GEN-004 Low Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 Low Dose + Adjuvant", "type": "BIOLOGICAL" }, { "name": "GEN-004 Mid Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 Mid Dose + Adjuvant", "type": "BIOLOGICAL" }, { "name": "GEN-004 High Dose", "type": "BIOLOGICAL" }, { "name": "GEN-004 High Dose + Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 90, "start_date": "2013-11", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-12-11", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995617" }, { "nct_id": "NCT03049488", "title": "Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "VRC-RSVRGP084-00-VP", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 95, "start_date": "2017-02-22", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049488" }, { "nct_id": "NCT06007183", "title": "Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chikungunya Virus Infection" ], "interventions": [ { "name": "CHIKV VLP vaccine booster", "type": "BIOLOGICAL" }, { "name": "Placebo booster", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 715, "start_date": "2023-08-30", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 24, "location_summary": "Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06007183" }, { "nct_id": "NCT02935686", "title": "A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140 plus adjuvant", "type": "BIOLOGICAL" }, { "name": "Clade C gp140/Mosaic gp140 plus adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "gp140 HIV Bivalent Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2017-03-31", "completion_date": "2023-11-22", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935686" }, { "nct_id": "NCT00280033", "title": "H5 Adult - Chiron Study of Bird Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" }, { "name": "Inactivated Influenza A/H5N1 Vaccine (Chiron)", "type": "BIOLOGICAL" }, { "name": "MF-59", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 394, "start_date": "2006-02", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-09-13", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 4, "location_summary": "Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280033" }, { "nct_id": "NCT00120081", "title": "Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hookworm Infection" ], "interventions": [ { "name": "Na-ASP-2/Alhydrogel Hookworm Vaccine", "type": "BIOLOGICAL" }, { "name": "Saline placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 36, "start_date": "2005-04", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120081" }, { "nct_id": "NCT01376765", "title": "Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SARS" ], "interventions": [ { "name": "Aluminum hydroxide adjuvant (Alhydrogel®)", "type": "DRUG" }, { "name": "Phosphate buffered saline Placebo", "type": "OTHER" }, { "name": "Recombinant S protein SARS vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 3, "location_summary": "Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376765" }, { "nct_id": "NCT03382418", "title": "Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp145 C.6980 Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2017-12-27", "completion_date": "2019-09-25", "has_results": true, "last_update_posted_date": "2021-10-08", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03382418" }, { "nct_id": "NCT03480802", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2018-07-06", "completion_date": "2020-01-17", "has_results": true, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 4, "location_summary": "Orlando, Florida • West Palm Beach, Florida • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480802" }, { "nct_id": "NCT03565900", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 277, "start_date": "2018-09-12", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-09-30T06:39:14.199Z", "location_count": 13, "location_summary": "Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565900" } ] }